Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Biosimilars United States Private Payers

US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab

  • News

Executive Summary

Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.

You may also be interested in...



Pfizer Lines Up Trio Of US Biosimilar Launches

By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.

Pfizer Prepares For Year-End US Bevacizumab Launch

Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.

US Distributor Demands Better Biosimilars Support

Removing legal hurdles and putting biosimilars on preferred formulary tiers will increase access and cut the cost of biologic therapies in the US, argues the chief of major healthcare distributor AmerisourceBergen.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars United States Private Payers
UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By